Key Financial Inc Has $2.10 Million Position in Pfizer Inc. (NYSE:PFE)

Key Financial Inc lowered its position in Pfizer Inc. (NYSE:PFE) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 73,092 shares of the biopharmaceutical company’s stock after selling 3,512 shares during the period. Key Financial Inc’s holdings in Pfizer were worth $2,104,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its holdings in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $255,000. Brookstone Capital Management grew its holdings in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the last quarter. ETF Store Inc. grew its holdings in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the last quarter. Finally, Farmers Trust Co. grew its holdings in Pfizer by 2.0% during the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after purchasing an additional 4,410 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Down 1.1 %

PFE stock traded down $0.27 during midday trading on Wednesday, reaching $25.42. The stock had a trading volume of 43,604,913 shares, compared to its average volume of 42,571,164. The business has a fifty day simple moving average of $27.23 and a two-hundred day simple moving average of $28.79. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $143.94 billion, a price-to-earnings ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.26 and a twelve month high of $41.33.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% on a year-over-year basis. During the same period last year, the company earned $1.14 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.